U.S. Bio Executives Receive Stock Options Worth Hundreds of Millions

Alto Neuroscience, Inc. (NASDAQ: ANRO) disclosed on February 11 that it has granted stock options in the U.S. to CEO Amit Etkin and CFO/CBO Nicholas Conrad Smith. Etkin received options to purchase 306,000 shares of common stock at an exercise price of $16.71 per share, while Smith received options for 200,000 shares at the same price. The total nominal values of these awards are approximately $5.1 million and $3.34 million, respectively (roughly KRW 67 billion and KRW 44 billion), and they vest over four years. These grants are rights to buy shares in the future, not current cash transactions.

On February 13, the company announced that it has completed patient enrollment in the Phase 2 proof-of-concept trial of ALTO-101, targeting cognitive impairments in schizophrenia patients. Alto Neuroscience currently has a market capitalization of about $500 million, with its stock trading in the mid-$16 range.

Headquartered in Mountain View, California, Alto Neuroscience is a clinical-stage biotech company using a precision-psychiatry platform to develop tailored treatments for subgroups of brain-disorder patients, such as those with depression and schizophrenia. Its lead pipeline candidates include ALTO-101 for schizophrenia-related cognitive impairment, ALTO-207 for treatment-resistant depression, ALTO-300 as an adjunct therapy for major depressive disorder, and ALTO-100 for bipolar depression.